Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Miki Tateyama"'
Autor:
Hiroshi Nakatsumi, Yoshito Komatsu, Tetsuhito Muranaka, Satoshi Yuki, Yasuyuki Kawamoto, Kazuaki Harada, Masayoshi Dazai, Miki Tateyama, Yusuke Sasaki, Takuto Miyagishima, Yasushi Tsuji, Masaki Katagiri, Michio Nakamura, Susumu Sogabe, Kazuteru Hatanaka, Takashi Meguro, Tomoe Kobayashi, Atsushi Ishiguro, Osamu Muto, Yoshiaki Shindo, Masahito Kotaka, Takayuki Ando, Ryo Takagi, Naoya Sakamoto, Yu Sakata
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe first-line chemotherapy for patients with RAS and BRAF wild-type metastatic colorectal cancer (mCRC) commonly involves cytotoxic regimens, such as FOLFOX and FOLFIRI, combined with epidermal growth factor receptor (EGFR) antibodies. Whe
Externí odkaz:
https://doaj.org/article/aab8f05946ed4eb79d1f6def13b45094
Autor:
Kazuaki Harada, Takahiro Yamamura, Osamu Muto, Michio Nakamura, Susumu Sogabe, Kentaro Sawada, Shintaro Nakano, Masataka Yagisawa, Tetsuhito Muranaka, Masayoshi Dazai, Miki Tateyama, Yoshimitsu Kobayashi, Sosuke Kato, Kazuteru Hatanaka, Yasuyuki Kawamoto, Satoshi Yuki, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 4, p 1596 (2023)
The effects of UGT1A1 gene polymorphisms or prior irinotecan treatment on treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with unresectable pancreatic ductal adenocarcinoma (PDAC) are not es
Externí odkaz:
https://doaj.org/article/5749d54805624998b0a4cb951bdff5aa
Autor:
Ken Ito, Satoshi Yuki, Hiroshi Nakatsumi, Yasuyuki Kawamoto, Kazuaki Harada, Shintaro Nakano, Rika Saito, Takayuki Ando, Kentaro Sawada, Masataka Yagisawa, Atsushi Ishiguro, Masayoshi Dazai, Ichiro Iwanaga, Kazuteru Hatanaka, Atsushi Sato, Ryusuke Matsumoto, Yoshiaki Shindo, Miki Tateyama, Tetsuhito Muranaka, Masaki Katagiri, Isao Yokota, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
Publikováno v:
Supportive Care in Cancer. 30(6):5351-5359
Purpose Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in
Autor:
Masayoshi Dazai, Yuh Sakata, Kazuaki Harada, Isao Yokota, Ichiro Iwanaga, Hiroshi Nakatsumi, Masataka Yagisawa, Kentaro Sawada, Takayuki Ando, Ryusuke Matsumoto, R. Saito, Yasuyuki Kawamoto, Kazuteru Hatanaka, Miki Tateyama, M. Katagiri, Satoshi Yuki, Atsushi Sato, Yoshiaki Shindo, Tetsuhito Muranaka, Atsushi Ishiguro, Yoshito Komatsu, Ken Ito, Shintaro Nakano, Naoya Sakamoto
PurposeDysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c05628bffe9e3d0858060c0692b9efa3
https://doi.org/10.21203/rs.3.rs-1028179/v1
https://doi.org/10.21203/rs.3.rs-1028179/v1
Autor:
Tatsuya Yokoyama, Ken Ito, Satoshi Yuki, Hiroshi Nakatsumi, Takayuki Ando, Kentaro Sawada, Masataka Yagisawa, Atsushi Ishiguro, Masayoshi Dazai, Ichiro Iwanaga, Kazuteru Hatanaka, Atsushi Sato, Ryusuke Matsumoto, Yoshiaki Shindo, Miki Tateyama, Tetsuhito Muranaka, Masaki Katagiri, Isao Yokota, Yuh Sakata, Yoshito Komatsu
Publikováno v:
Annals of Oncology. 33:S477
Autor:
Masayoshi Dazai, Kazuaki Harada, Takahiro Yamamura, Osamu Muto, Michio Nakamura, Susumu Sogabe, Kentaro Sawada, Masataka Yagisawa, Tetsuhito Muranaka, Shintaro Nakano, Miki Tateyama, Ken Ito, Rika Saito, Yoshimitsu Kobayashi, Sosuke Kato, Takuto Miyagishima, Yasuyuki Kawamoto, Satoshi Yuki, Yuh Sakata, Yoshito Komatsu
Publikováno v:
Annals of Oncology. 33:S481
Autor:
Shintaro Nakano, Yasuyuki Kawamoto, Satoshi Yuki, Kazuaki Harada, Takuto Miyagishima, Susumu Sogabe, Masayoshi Dazai, Atsushi Sato, Atsushi Ishiguro, Michio Nakamura, Shinya Kajiura, Yasuo Takahashi, Miki Tateyama, Kazuteru Hatanaka, Yasushi Tsuji, Takahide Sasaki, Yoshiaki Shindo, Tomoe Kobayashi, Isao Yokota, Naoya Sakamoto, Yuh Sakata, Yoshito Komatsu
Publikováno v:
BMJ Open. 12(5):e048833
IntroductionCombination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) has become one of the standard treatments for metastatic pancreatic cancer. However, the use of FOLFIRINOX requires prolonged infusion. Theref
Autor:
Ken Ito, Satoshi Yuki, Hiroshi Nakatsumi, Takayuki Ando, Kentaro Sawada, Masataka Yagisawa, Atsushi Ishiguro, Masayoshi Dazai, Ichiro Iwanaga, Kazuteru Hatanaka, Atsushi Sato, Ryusuke Matsumoto, Yoshiaki Shindo, Miki Tateyama, Tetsuhito Muranaka, Masaki Katagiri, Isao Yokota, Yuh Sakata, Naoya Sakamoto, Yoshito Komatsu
Publikováno v:
Journal of Clinical Oncology. 40:649-649
649 Background: Dysgeusia is the one of important adverse events in patients treated with chemotherapy because it could reduce daily oral intake and worsen patient’s nutritional status. It is said that the lack of zinc is often observed in patients
Autor:
Michio Nakamura, Atsushi Ishiguro, Kentaro Sawada, Yoshiaki Shindo, Naoya Sakamoto, Atsushi Sato, Susumu Sogabe, Satoshi Yuki, Akira Ueda, Yasuyuki Kawamoto, Yoshito Komatsu, M. Katagiri, Takahide Sasaki, Kazuteru Hatanaka, Yasushi Tsuji, Ayumu Hosokawa, Masayoshi Dazai, Osamu Muto, Miki Tateyama, R. Saito
Publikováno v:
Journal of Clinical Oncology. 39:TPS4152-TPS4152
TPS4152 Background: Paclitaxel and ramucirumab combination therapy had become a standard regimen in the second-line treatment of advanced gastric cancer, since RAINBOW trial showed paclitaxel and ramucirumab combination therapy increased overall surv
Autor:
Mitsuteru Natsuizaka, Miki Tateyama, Hiromasa Horimoto, Keisuke Shinada, Seiji Tsunematsu, Goki Suda, Atsushi Nagasaka, Mineo Kudo, Machiko Umemura, Takaaki Izumi, Katsumi Terashita, Koji Ogawa, Takuya Sho, Ken Furuya, Yoko Tsukuda, Fumiyuki Sato, Masato Nakai, Naoya Sakamoto, Jun Konno, Megumi Kimura, Yoshiya Yamamoto, Kazushi Yamasaki, Tomoe Kobayashi, Kenichi Morikawa
Publikováno v:
Journal of gastroenterology. 51(7):733-740
Background: HCV infection in chronic hemodialysis patients is high, has a poor prognosis and high risk of renal graft failure, and requires nosocomial infection control measures. However, options of anti-HCV therapy in such patients are limited and u